Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: David L. Hachey who wrote (18504)	4/2/1998 1:21:00 PM
From: tuck	Read Replies (1) \| Respond to of 32384

Dave, A search of Ligand's publications on their retinoids that are available online has failed to turn up anything on the transient spike. Ligand's human trials have been for cancer, and transient TG levels are evidently not parameters in the protocols (though enrolled patients had to have a certain maximum fasting serum TG level, for instance 800ml/dL for the Phase II/III oral Targretin for CTCL trial). This does not mean they weren't measured, only that they didn't have to be publicized. To my knowledge, the effects of Ligand's retinoids on diabetic parameters beyond animal models haven't been published. But I am not the font of knowledge that Henry, for example, is. Maybe he or someone knows something about this that I am unaware of. So Henry, feel free to chime in here. It'll be a couple of weeks before I have a chance to find out the numbers, and I don't know what my chances are. Tuck